Role of Sentinel Lymph Node Biopsy in Non-Melanoma Skin Cancer
Author Information
Author(s): Borgognoni Lorenzo, Susini Pietro, Gerlini Gianni, Brandani Paola, Giannotti Vanni, Sestini Serena
Primary Institution: Santa Maria Annunziata Hospital, Florence, Italy
Hypothesis
The study investigates the role of Sentinel Lymph Node Biopsy (SLNB) in Non-Melanoma Skin Cancer (NMSC) and its effectiveness in identifying lymph node metastases.
Conclusion
SLNB should be considered for staging and prognostic purposes in patients with high-risk Non-Melanoma Skin Cancer.
Supporting Evidence
- SLNB positivity rate in NMSC was found to be 24.4%.
- SLNB detection rate was 97.6%, indicating high feasibility.
- Most studies concluded that SLNB is safe and significant for managing NMSC.
Takeaway
Doctors use a special test called Sentinel Lymph Node Biopsy to check if skin cancer has spread to nearby lymph nodes, which helps them decide the best treatment.
Methodology
A PRISMA systematic review was conducted on studies from PubMed (MEDLINE) from 2004 to 2024, focusing on SLNB in NMSC.
Potential Biases
Different criteria for defining high-risk SCC may introduce bias in the results.
Limitations
The definition of 'high risk' SCC varies across studies, and the review only included articles from PubMed.
Participant Demographics
The average age of participants was 65 years, with 45.5% females and 54.5% males.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website